Initiate at least one clinical trial for primary prevention of AD and AD-related dementias among high risk individuals in midlife including a non-pharmacological treatment arm.
Completion of at least one Phase II primary prevention trial for non-pharmacological interventions in midlife. Successful trials will provide evidence for potential therapeutic mechanisms and include the collection of biomarker data for future validation and longitudinal follow-up within the trial cohort.
Summary of Key Accomplishments
In 2021, NIA held a workshop to review non-pharmacological approaches for early prevention of AD/ADRD. The goal of this workshop was to address the core methodological challenges associated with developing and accumulating evidence to support preventive interventions for AD/ADRD with respect to the populations, targets, and outcomes that should be the focus of the prevention research agenda.
This information is current as of March 2022.
- Research Implementation Area
- Non-Pharmacological Interventions
- In Progress
Research Programs and Resources
- Long-term Impact of Random Assignment to Intensive Lifestyle Intervention on Alzheimer’s Disease and Related Dementias: The Action for Health in Diabetes ADRD Study (Look AHEAD-MIND)